Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cllc.2023.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fibroblast growth factor therapies in biliary tract cancers: current and future state.
Expert Opin Investig Drugs
December 2024
Department of Oncology, Case Western Reserve University, Cleveland, OH, USA.
Article Synopsis
- Cholangiocarcinoma is a rare and aggressive cancer with a poor outlook, but recent advances in targeted therapies focus on a specific pathway known as FGFR which is linked to its development.
- Current FGFR-targeted treatments, like pemigatinib and futibatinib, have been approved and show promise, but many patients either don't respond or develop resistance over time.
- Researchers are exploring new FGFR inhibitors to enhance effectiveness and minimize side effects, aiming to improve patient outcomes and quality of life.
Synthetic Retinoid Sulfarotene Selectively Inhibits Tumor-Repopulating Cells of Intrahepatic Cholangiocarcinoma via Disrupting Cytoskeleton by P-Selectin/PSGL1 N-Glycosylation Blockage.
Adv Sci (Weinh)
January 2025
Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Intrahepatic cholangiocarcinoma (ICC) is a highly lethal malignancy that currently lacks effective clinical treatments. Eliminating stem cell-like cancer cells is an extremely promising but challenging strategy for treating ICC. A recently developed synthetic retinoid, sulfarotene, abrogates proliferation, and induces apoptosis of tumor-repopulating cells (TRCs) that exhibit stem cell-like properties, yet its effect and underlying mechanisms remain elusive in ICC.
View Article and Find Full Text PDFPractical Management of Adverse Events Associated With FGFR Inhibitors for Cholangiocarcinoma for the Advanced Practice Provider.
J Adv Pract Oncol
February 2024
National Community Oncology Dispensing Association, Cazenovia, New York.
Article Synopsis
- Cholangiocarcinoma is a bile duct cancer often diagnosed late, leading to poor prognosis, but selective FGFR inhibitors show promise in treating it, especially in cases with specific genetic alterations.
- These FGFR inhibitors can cause side effects like hyperphosphatemia, fatigue, and other gastrointestinal and dermatological issues, which need to be managed proactively to improve treatment adherence and patient outcomes.
- A multidisciplinary care team including various healthcare professionals is essential, with practical guidance provided on managing side effects, considering interactions with other medications or foods, and offering supportive care recommendations for patients.
Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US.
Oncologist
August 2024
Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Background: Pemigatinib demonstrated efficacy in fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA) in the FIGHT-202 trial. However, limited real-world evidence exists on treatment patterns and outcomes in this setting.
Patients And Methods: Patient characteristics, treatment patterns, and outcomes of US adults who received pemigatinib for unresectable, locally advanced or metastatic CCA were collected via retrospective physician-abstracted chart review.
Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib.
Crit Rev Oncol Hematol
October 2024
Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena, Rome 324 -00161, Italy.
Fibroblast Growth Factor Receptors (FGFRs) are emerging as key factors involved in tumorigenesis, tumor microenvironment remodeling and acquired resistance to targeted therapies. Pemigatinib is a Tyrosine-Kinase Inhibitor that selectively targets aberrant FGFR1, FGFR2 and FGFR3. Pemigatinib is now approved for advanced-stage cholangiocarcinoma (CCA) but data suggests that other tumor histotypes exhibit FGFR alterations, thus hypothesizing its potential efficacy in other cancer settings.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!